This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today provided an overview of selected studies that will be presented at IDWeek, the first combined meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), and the Pediatric Infectious Diseases Society (PIDS), taking place taking place from October 17
th to 21
st in San Diego. The studies focus on the company’s late-stage investigational antibiotic, CXA-201 (ceftolozane/tazobactam), as well as on CUBICIN® (daptomycin for injection).
“The data we are presenting at IDWeek underscore the potential of our late-stage pipeline as well as broaden our understanding of the clinical importance of CUBICIN,” said Cubist’s Chief Scientific Officer Steve Gilman, PhD. “We are pleased that these new
in vitro data on CXA-201 continue to show a promising profile of activity and we look forward to the results of the pivotal Phase 3 studies.”
A list of selected presentations can be found on the company’s
website. Key highlights include:
CXA-201 (ceftolozane/tazobactam)CXA-201, a novel cephalosporin in combination with tazobactam, is in development for the treatment of certain serious infections caused by multi-drug resistant (MDR) Gram-negative organisms, particularly
Pseudomonasaeruginosa and those in the
This year at IDWeek, two important studies on CXA-201 will be presented. In these two studies, CXA-201 showed significant potency in vitro when tested against Enterobacteriaceae and
P. aeruginosa strains from hospitals in the United States or Canada.
Activity of the Novel Antimicrobial Combination Ceftolozane/Tazobactam, Tested Against Bacterial Isolates in USA Hospitals from Patients with Pneumonia (2011) (Presentation 846) Friday, October 19, 2012, 12:30 p.m. - 2:00 p.m. PDT, Poster Hall F-H.
in Vitro Activity of Ceftolozane/Tazobactam versus Pseudomonas aeruginosa Isolates Obtained from Patients in Canadian Hospitals: CANWARD 2011 (Presentation 1616) Saturday, October 20, 2012, 12:30 p.m. - 2:00 p.m. PDT, Poster Hall F-H.
CUBICIN (daptomycin for injection)Thirteen scientific abstracts at IDWeek feature daptomycin. New data on at-home infusion of daptomycin compared to vancomycin are presented. These new data show that adverse event rates were similar between the two therapies. Another important study outlines key pharmacokinetic parameters and dosing implications in pediatric patients.
Safety and Clinical Outcomes of Daptomycin at Doses of ≥10 mg/kg (Presentation 779) Friday, October 19, 2012, 12:30 p.m. - 2:00 p.m. PDT, Poster Hall F-H.
Adverse Events and Healthcare Utilization during Home Infusion Therapy with Daptomycin and Vancomycin (Presentation 794) Friday, October 19, 2012, 12:30 p.m. - 2:00 p.m. PDT, Poster Hall F-H.
Pharmacokinetics of Daptomycin in Pediatric Patients 3 to 24 Months of Age: Implications for Dosing (Presentation 788) Friday, October 19, 2012, 12:30 p.m. - 2:00 p.m. PDT, Poster Hall F-H.
About CUBICINCUBICIN® (daptomycin for injection) is approved in the U.S. and many other non-US markets as therapy for
Staphylococcus aureus bloodstream infections (bacteremia), including right-sided endocarditis, caused by methicillin-resistant
S. aureus (MRSA) and methicillin-susceptible
S. aureus (MSSA), and complicated skin infections caused by certain Gram-positive bacteria, including MRSA. CUBICIN is not indicated for the treatment of pneumonia. Most adverse events reported in clinical trials were mild to moderate in intensity. The most common were anemia, constipation, diarrhea, nausea, vomiting, injection site reactions, and headache. To reduce the development of drug-resistant bacteria and maintain the effectiveness of CUBICIN, CUBICIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria susceptible to CUBICIN. For full prescribing information, including important safety information, please visit
About CubistCubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address significant unmet medical needs in the acute care environment. Cubist is headquartered in Lexington, Mass. Additional information can be found at Cubist’s web site at